102 related articles for article (PubMed ID: 20482528)
41. Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers.
Page DB; Yuan J; Wolchok JD
Immunotherapy; 2010 May; 2(3):367-79. PubMed ID: 20635901
[TBL] [Abstract][Full Text] [Related]
42. Update on anti-CTLA-4 antibodies in clinical trials.
Langer LF; Clay TM; Morse MA
Expert Opin Biol Ther; 2007 Aug; 7(8):1245-56. PubMed ID: 17696822
[TBL] [Abstract][Full Text] [Related]
43. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications.
Di Giacomo AM; Biagioli M; Maio M
Semin Oncol; 2010 Oct; 37(5):499-507. PubMed ID: 21074065
[TBL] [Abstract][Full Text] [Related]
44. Checkpoint blockade in cancer immunotherapy.
Korman AJ; Peggs KS; Allison JP
Adv Immunol; 2006; 90():297-339. PubMed ID: 16730267
[TBL] [Abstract][Full Text] [Related]
45. Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma.
Comin-Anduix B; Sazegar H; Chodon T; Matsunaga D; Jalil J; von Euw E; Escuin-Ordinas H; Balderas R; Chmielowski B; Gomez-Navarro J; Koya RC; Ribas A
PLoS One; 2010 Sep; 5(9):e12711. PubMed ID: 20856802
[TBL] [Abstract][Full Text] [Related]
46. Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis.
Bostwick AD; Salama AK; Hanks BA
J Immunother Cancer; 2015; 3():19. PubMed ID: 25992290
[TBL] [Abstract][Full Text] [Related]
47. Melanoma vaccines and modulation of the immune system in the clinical setting: building from new realities.
Madorsky-Rowdo FP; Lacreu ML; Mordoh J
Front Immunol; 2012; 3():103. PubMed ID: 22566975
[TBL] [Abstract][Full Text] [Related]
48. What are the Optimal Systemic Treatment Options for Rhabdomyosarcoma?
Miwa S; Hayashi K; Taniguchi Y; Asano Y; Demura S
Curr Treat Options Oncol; 2024 May; ():. PubMed ID: 38750399
[TBL] [Abstract][Full Text] [Related]
49. Potential clinical implications of CD4
Galati D; Zanotta S; Capone M; Madonna G; Mallardo D; Romanelli M; Simeone E; Festino L; Sparano F; Azzaro R; De Filippi R; Pinto A; Paulos CM; Ascierto PA
J Transl Med; 2023 May; 21(1):318. PubMed ID: 37170241
[TBL] [Abstract][Full Text] [Related]
50. A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412.
Davis KL; Fox E; Isikwei E; Reid JM; Liu X; Minard CG; Voss S; Berg SL; Weigel BJ; Mackall CL
Clin Cancer Res; 2022 Dec; 28(23):5088-5097. PubMed ID: 36190525
[TBL] [Abstract][Full Text] [Related]
51. Immune Checkpoints in Cancers: From Signaling to the Clinic.
Pisibon C; Ouertani A; Bertolotto C; Ballotti R; Cheli Y
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572799
[TBL] [Abstract][Full Text] [Related]
52. T-Regulatory Cells In Tumor Progression And Therapy.
Verma A; Mathur R; Farooque A; Kaul V; Gupta S; Dwarakanath BS
Cancer Manag Res; 2019; 11():10731-10747. PubMed ID: 31920383
[TBL] [Abstract][Full Text] [Related]
53. The Role of the Lymphocyte Functional Crosstalk and Regulation in the Context of Checkpoint Inhibitor Treatment-Review.
Seliger B
Front Immunol; 2019; 10():2043. PubMed ID: 31555274
[TBL] [Abstract][Full Text] [Related]
54. Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy.
Warner BM; Baer AN; Lipson EJ; Allen C; Hinrichs C; Rajan A; Pelayo E; Beach M; Gulley JL; Madan RA; Feliciano J; Grisius M; Long L; Powers A; Kleiner DE; Cappelli L; Alevizos I
Oncologist; 2019 Sep; 24(9):1259-1269. PubMed ID: 30996010
[TBL] [Abstract][Full Text] [Related]
55. The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.
Kvarnhammar AM; Veitonmäki N; Hägerbrand K; Dahlman A; Smith KE; Fritzell S; von Schantz L; Thagesson M; Werchau D; Smedenfors K; Johansson M; Rosén A; Åberg I; Winnerstam M; Nyblom E; Barchan K; Furebring C; Norlén P; Ellmark P
J Immunother Cancer; 2019 Apr; 7(1):103. PubMed ID: 30975201
[TBL] [Abstract][Full Text] [Related]
56. p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses.
Hardwick NR; Carroll M; Kaltcheva T; Qian D; Lim D; Leong L; Chu P; Kim J; Chao J; Fakih M; Yen Y; Espenschied J; Ellenhorn JD; Diamond DJ; Chung V
Clin Cancer Res; 2014 Sep; 20(17):4459-70. PubMed ID: 24987057
[TBL] [Abstract][Full Text] [Related]
57. Gut microbiota and the paradox of cancer immunotherapy.
Poutahidis T; Kleinewietfeld M; Erdman SE
Front Immunol; 2014; 5():157. PubMed ID: 24778636
[TBL] [Abstract][Full Text] [Related]
58. Inhibitory receptors on lymphocytes: insights from infections.
Odorizzi PM; Wherry EJ
J Immunol; 2012 Apr; 188(7):2957-65. PubMed ID: 22442493
[TBL] [Abstract][Full Text] [Related]
59. The Role of Regulatory T Cells in Mesothelioma.
Ireland DJ; Kissick HT; Beilharz MW
Cancer Microenviron; 2012 Aug; 5(2):165-72. PubMed ID: 22302659
[TBL] [Abstract][Full Text] [Related]
60. Immunotherapy for prostate cancer: biology and therapeutic approaches.
Cha E; Fong L
J Clin Oncol; 2011 Sep; 29(27):3677-85. PubMed ID: 21825260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
